Home | Medical-Newswire.Com:
(Medical-NewsWire.com, March 11, 2018 ) Argatroban is a synthetic direct thrombin inhibitor and the chemical name is 1-[5- [(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic acid, monohydrate. Argatroban has 4 asymmetric carbons. One of the asymmetric carbons has an R configuration (stereoisomer Type I) and an S configuration (stereoisomer Type II). Argatroban consists of a mixture of R and S stereoisomers at a ratio of approximately 65:35.
Browse Market Data Tables and In-Depth TOC of the Argatroban Market to 2023 @ https://www.researchcosmos.com/reports/global-argatroban-market-trends-competitive-dynamics-and-key-growth-opportunities-2015-t/1847033769
This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions.
Request Free Sample @ https://www.researchcosmos.com/request/1847033769
Market Segment as follows:
By Region / Countries
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain etc)
South America (Brazil, Argentina etc)
Middle East & Africa (Saudi Arabia, South Africa etc)
By End-User / Application
Heparin-induced thrombocytopenia (HIT)
Percutaneous Coronary Intervention
Cerebral arterial thrombosis
Mitsubishi Tanabe Pharma
Teva Pharmaceutical Industries
Inquire before buying @ https://www.researchcosmos.com/inquire/1847033769
Research Cosmos is an aggregator of syndicated and bespoke market research, business intelligence and consulting services on gamut of sectors across the globe. Were associated with world renowned publishers who when combined, serve hundreds of fortune listed companies and publish wide range of insightful reports which cover nook and corner of every industry vertical.
+1 888 709 8757
+1 888 709 8757